FAQ

JNJ-40346527

Known as: FMS Inhibitor JNJ-40346527 
A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. FMS… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2018
012320152018

Related topics

Related topics

5 relations

Broader (2)

ImidazolesPyridines
Inhibition of Cell ProliferationReceptor Tyrosine Kinase InhibitionSignal Transduction Inhibition

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
JNJ-40346527
Pyridines
Imidazoles
Inhibition of Cell Proliferation
Receptor Tyrosine Kinase Inhibition
Signal Transduction Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications.
Colony stimulating factor-1 (CSF-1) is one of the most common proinflammatory cytokine responsible for various inflammatory… (More)
Is this relevant?
2016
2016
Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin
In the present work we show that multiple lung cancer cell lines contain cisplatin resistant cell subpopulations expressing the… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
OBJECTIVE To assess the efficacy and safety of JNJ-40346527, a selective inhibitor of colony-stimulating factor-1 (CSF-1… (More)
Is this relevant?
2015
2015
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma.
PURPOSE This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2015
2015
Cancer Therapy: Clinical An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, aCSF-1R Inhibitor, inPatientswith Relapsed or Refractory Hodgkin Lymphoma
Purpose: This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?